Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • Searching Asian documents: patent search and monitoring services
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet and OPS
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Patent insight reports
    • Data
      • Overview
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge

    UP search

    Learn about the Unitary Patent in patent knowledge products and services

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Find a professional representative
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Unitary Patent

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • EPC Guidelines
      • PCT-EPO Guidelines
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National law relating to the UP
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives

    legal text

    Legal texts

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2022 ceremony
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Firefighting technologies
      • Green tech in focus
      • CodeFest on Green Plastics
      • Clean energy technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    Listen to our podcast

  • Learning

    Learning

    The e-Academy – the point of access to your learning

    Go to overview 

    • Overview
    • European Patent Academy
      • Overview
      • Learning activities
      • Learning paths
    • Professional hub
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by area by profile
      • Overview
      • Business and IP managers
      • EQE candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)

    European Patent Academy

    Boost your IP knowledge with (e-)training from the European Patent Academy

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • A glimpse of the planned activities
      • Kids’ collaborative art competition
      • 50 Leading Tech Voices
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Governance
      • Overview
      • Communiqués
      • Calendar
      • Select Committee documents
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Public consultation on the EPO's Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Social responsibility
      • Overview
      • Environment and sustainability
      • Art collection
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s

    about us

    Patent Index 2022

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
  • New to patents
    • Go back
    • Overview
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Your business and patents
    • Is it patentable?
    • Are you first?
    • Why do we have patents?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • Searching Asian documents
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
            • Go back
            • Overview
            • BG - Federated Register Service
            • GB - Federated Register Service
            • NL - Federated Register Service
            • MK - Federated Register Service
            • ES - Federated Register Service
            • GR - Federated Register Service
            • SK - Federated Register Service
            • FR - Federated Register Service
            • MT - Federated Register Service
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Patent insight reports
    • Data
      • Go back
      • Overview
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
          • Go back
          • EBD files (weekly download) - free of charge
            • Go back
            • Secure EBD ST.36 files (weekly download) - for national patent offices only
        • Boards of Appeal decisions
        • EP full-text data for text analytics
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Helpful resources
      • Go back
      • Overview
      • First time here? Patent information explained.
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Unitary Patent Guide
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Online Filing 2.0 pilot
        • MyEPO Portfolio - pilot phase
        • Online Filing 2.0 pilot continuation
        • Exchange data with us using an API
      • Get access
        • Go back
        • Overview
        • Installation and activation
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • EPC Guidelines
        • Go back
        • Overview
        • Archive
      • PCT-EPO Guidelines
        • Go back
        • Overview
        • Archive
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2023 ceremony
      • European Inventor Network
        • Go back
        • Activities granted in 2023
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • CodeFest on Green Plastics
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Patents and standards
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • European Patent Academy
      • Go back
      • Overview
      • Learning activities
      • Learning Paths
    • Professional hub
      • Go back
      • Overview
      • EPAC - European patent administration certification
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Archive
        • Candidates successful in the European qualifying examination
        • Compendium
          • Go back
          • Overview
          • Pre-examination
          • Paper A
          • Paper B
          • Paper C
          • Paper D
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
        • Go back
        • Overview
        • Patent enforcement in Europe
        • Patent litigation in Europe
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventors' handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
            • Go back
            • Overview
            • Is the idea ‘obvious’?
            • Prior art searching
            • Professional patent searching
            • Simple Espacenet searching
            • What is prior art?
            • Why is novelty important?
          • Competition and market potential
            • Go back
            • Overview
            • Research guidelines
          • Assessing the risk ahead
            • Go back
            • Overview
            • Exploitation routes
            • Significant commercial potential
            • Significant novelty
            • What about you?
            • What if your idea is not novel but does have commercial potential?
          • Proving the invention
            • Go back
            • Overview
            • Help with design or redesign
            • Prototype strategy
          • Protecting your idea
            • Go back
            • Overview
            • Forms of IPR
            • Patenting strategy
            • The patenting process
          • Building a team and seeking funding
            • Go back
            • Overview
            • Building a team
            • Sources of funding
            • Sources of help for invention
          • Business planning
            • Go back
            • Overview
            • Constructing a business plan
            • Keep it short!
          • Finding and approaching companies
            • Go back
            • Overview
            • First contact
            • Meetings
          • Dealing with companies
            • Go back
            • Overview
            • Advance or guaranteed payment
            • Companies and your prototype
            • Full agreement – and beyond
            • Negotiating a licensing agreement
            • Reaching agreement
            • Royalties
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • For IP professionals
          • For business decision-makers
          • For stakeholders of the innovation ecosystem
        • IP clinics
      • EQE Candidates
        • Go back
        • Overview
        • Coffee-break questions
        • Daily D questions
        • European qualifying examination - Guide for preparation
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Overview
      • 50 Leading Tech Voices
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Governance
      • Go back
      • Overview
      • Communiqués
        • Go back
        • Overview
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • Invoicing
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • Social responsibility
      • Go back
      • Overview
      • Environment
      • Art collection
        • Go back
        • Overview
        • The collection
        • Let's talk about art
        • Artists
        • Media library
        • What's on
        • Publications
        • Contact
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Procedure
    • Annual reports
      • Go back
      • Overview
    • Organisation
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
        • Composition of the Presidium
          • Go back
          • Overview
          • Archive
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2023
      • Archive
    • Annual list of cases
    • Communications
    • Publications
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
    • Case Law from the Contracting States to the EPC
    • Oral proceedings
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Legal resources
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
      • Specific contact
      • Surveys
        • Go back
        • Overview
        • Search services
        • Examination services, final actions and publication
        • Opposition services
        • Patent filings
          • Go back
          • Overview
          • Detailed methodology
          • Archive
        • Online Services
        • Patent information
          • Go back
          • Overview
          • Innovation process survey
        • Customer services
        • Filing services
        • Website
        • Survey on electronic invoicing
        • Companies innovating in clean and sustainable technologies
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Forums
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2023 decisions
  • 2022 decisions
  • 2021 decisions
https://www.epo.org/en/node/t950241ex1
  1. Home
  2. T 0241/95 (Serotonin receptor/ELI LILLY) 14-06-2000
Facebook Twitter Linkedin Email

T 0241/95 (Serotonin receptor/ELI LILLY) 14-06-2000

European Case Law Identifier
ECLI:EP:BA:2000:T024195.20000614
Date of decision
14 June 2000
Case number
T 0241/95
Petition for review of
-
Application number
91302599.5
IPC class
A61K 31/135
Language of proceedings
EN
Distribution
PUBLISHED IN THE EPO'S OFFICIAL JOURNAL (A)

Download and more information:

Decision in EN 33.5 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Oj
Published
Application title

Use of R-Fluoxetine as selective serotonin IC-receptor ligands

Applicant name
ELI LILLY AND COMPANY
Opponent name
-
Board
3.3.02
Headnote

I. The selective occupation of a receptor cannot be considered in itself as a therapeutic application; the discovery that a substance selectively binds a receptor, even if representing an important piece of scientific knowledge, still needs to find a practical application in the form of a defined, real treatment of any pathological condition in order to make a technical contribution to the art and to be considered as an invention eligible for patent protection (see reasons, point 3.1.2).

II. When a claim is directed to a further therapeutic application of a medicament and the condition to be treated is defined in functional terms, e.g. any condition susceptible of being improved or prevented by selective occupation of a specific receptor, the claim can be regarded as clear only if instructions, in the form of experimental tests or any testable criteria, are available from the patent documents or from the common general knowledge allowing the skilled person to recognise which conditions fall within the functional definition and accordingly within the scope of the claim (see reasons, point 3.1.1) (following T 68/85, Synergistic herbicides/ CIBA-GEIGY, OJ EPO 1987, 228).

Relevant legal provisions
European Patent Convention Art 84 1973
European Patent Convention Art 54 1973
European Patent Convention Art 111(1) 1973
Keywords

Main request: clarity of the functional definition (no)

First auxiliary request: novelty (no); therapeutic effect already described in animals

Second auxiliary request: specific diseases never considered by the Examining Division - remittal to the department of first instance

Catchword
-
Cited decisions
T 0068/85
T 0158/96
Citing decisions
T 1031/00
T 0609/02
T 0462/06
T 0385/07
T 1911/08
T 0814/12
T 2321/13
T 2251/14
T 0752/17
T 0395/18
T 1045/98
T 1048/98
W 0018/03
W 0023/03
T 1868/19

I. European patent application No. 91 302 599.5 (publication No. 0 449 562) was refused by the examining division under Article 97(1) EPC on the grounds of lack of clarity and lack of inventive step of the subject-matter of claim 1. The decision was taken on the basis of a single claim 1 filed with a letter dated 4 August 1994 and reading as follows:

"The use of (R)-fluoxetine, that is (R)-fluoxetine substantially free of (S)-fluoxetine, or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for treating a mammal suffering from or susceptible to a condition which can be improved or prevented by selective occupation of the 5-HTIC receptor"

II. The following documents were considered inter alia during the examination proceedings:

(1) Journal of Medical Chemistry, Vol. 31, No. 7, 1998, pages 1412-1417 (D. W. Robertson et al.);

(3) Psychopharmacology, Vol. 99, 1989, pages 196-201 (J.C. Neill et al.);

A further document, not belonging to the state of the art, was also cited in the European search report as being a document useful for understanding the invention:

(4) Neuropsychopharmacology, Vol. 5, No. 1, August 1991, pages 43-47 (D. T. Wong, P. G. Threlkeld, D. W. Robertson).

III. The examining division held that claim 1 under consideration was unclear because it characterised the matter for which protection was sought by way of a functional definition, but the application did not provide the skilled person with the necessary teaching for assessing what subject-matter was actually comprised in this definition. In fact, although the scope of the claim was not limited to the specific examples of "conditions" disclosed in the description, no test or other indication could be derived from the application in suit or the common general knowledge to recognise all other conditions improved or prevented by the selective occupation of the 5-HTIC receptor and, accordingly, comprised in the scope of the claim.

For this reason the claim was not considered to meet the requirements of Article 84 EPC.

In addition, the examining division also held that the claimed subject-matter did not involve an inventive step.

In the examining division's opinion, document (1) already suggested the use of fluoxetine in racemic form in the treatment of conditions also cited in the application in suit. Therefore the use of the (R)-isomer of fluoxetine for the treatment of similar conditions was regarded as obvious. Nor could the disclosed specificity of the (R)-isomer for the 5-HTIC receptor endow the claimed subject-matter with an inventive step, since, according to the examining division, this property was derivable from the teaching of document (3).

IV. The appellant lodged an appeal against this decision and filed as main request a set of 4 claims having the same claim 1 as that considered by the examining division and further auxiliary requests on 24. February 1995.

V. With a communication issued on 14 June 1999, the following new prior-art document was introduced by the Board into the proceedings:

(5) The Journal of Neuropsychiatry and Clinical Neurosciences, Vol. 1, No. 3, summer 1989, pages 253-262 (S. J. Peroutka et al.)

VI. In reply to the official communication, the appellant produced additional documents and experimental results, namely tests showing the different specificity of fluoxetine racemate, (R)-isomer and (S)-isomer on the 5-HTIC receptor, and tests showing the pharmacological effect on animal models of (R)-fluoxetine in migraine, obsessive compulsive disorder (OCD) and pain.

VII. At the oral proceedings, which were held on 14. June 2000, the appellant maintained an unchanged main request, but filed new first, second, third and fourth auxiliary requests.

Claim 1 of the main request is the same as that considered in the decision under appeal. The two claims 1 according to the first and second auxiliary requests read as follows:

First auxiliary request

"The use of (R)-fluoxetine, that is (R)-fluoxetine substantially free of (S)-fluoxetine, or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for treating a mammal suffering from or susceptible to obesity, bulimia, alcoholism, pain, sleep apnea, obsessive-compulsive disorders, substance abuse or migraine"

Second auxiliary request

"The use of (R)-fluoxetine, that is (R)-fluoxetine substantially free of (S)-fluoxetine, or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for treating a mammal suffering from or susceptible to sleep apnea, substance abuse or migraine".

Claims 1 of the third and fourth auxiliary requests related to sleep apnea and to migraine respectively.

VIII. The appellant argued in writing and during the oral proceedings that the invention was based on the discovery that the (R)-isomer of fluoxetine showed an unexpectedly high selectivity for the 5-HTIC receptor. This property offered the advantage that, at a given dosage level, (R)-fluoxetine was potentially free of side effects due to unspecific binding at other receptors.

With regard to the objection raised by the examining division that there was an undue burden in identifying all the conditions embraced by claim 1 (present main request), the appellant argued that the selective binding to the 5-HTIC receptor already in itself pointed to conditions in relation to CNS disorders and that many animal models were available for assessing the development of such disorders. On the other hand, a list of such conditions was given in the description which did not need to be exhaustive but simply indicative.

Moreover, the efficacy of (R)-fluoxetine in treating migraine, pain and OCD was shown with the experimental tests produced in Annex Z. However, during the discussion of these tests, the appellant admitted that there was no conclusive evidence or demonstration showing that the observed therapeutic effects were due to the specific 5-HTIC receptor occupation rather than to the concomitant inhibition of the serotonin synaptic uptake, which was indeed the predominant fluoxetine pharmacological effect.

IX. The appellant requested that the decision of the examining division be set aside and the patent be granted on the basis of the main request; alternatively on the basis of one of the four auxiliary requests, all as submitted during the oral proceedings.

1. The appeal is admissible.

2. Article 123(2) EPC

Claim 1 according to all the requests includes the passage "that is (R)-fluoxetine substantially free of (S)-fluoxetine" which was not present in the text of the filed application. From a reading of the original description, it is immediately understood that the invention is directed to the use of the sole (R)-isomer, which is cited in the third and fourth paragraphs of page 1 as the form according to the invention as opposed to the known racemic form. The description also cites several known standard methods for resolving the racemate into the (R) and (S) isomers and for preparing the pure (R)-form (see lines 12 to 24 on page 3). Therefore, the Board can conclude that the application as filed implicitly disclosed the use of the (R)-fluoxetine free of the (S)-isomer.

As regards the deletion of the passage "a condition which can be improved or prevented by selective occupation of the 5HTIC receptor", from the text of claim 1 according to all the auxiliary requests the Board notes that this feature of the originally claimed subject-matter has been replaced by specific diseases cited in the original application as examples of such a "condition". Since the Board has no means or reason to confute the validity of the statement in the description that these specific conditions are improved or prevented by the selective occupation of the 5HTIC receptor, the amendment is held not to extend the content of the application as filed.

Therefore, the Board considers that the amended claims according to all the requests comply with the requirements of Article 123(2) EPC.

3. Main request

3.1. Article 84 EPC

3.1.1. Claim 1 defines the disease or disorder to be treated with (R)-fluoxetine as a condition which is capable of being improved or prevented by selective occupation of the 5-HTIC receptor. The functional terms used to define the condition to be treated are acceptable as long as the claim still meets the requirements of Article 84 EPC. According to decision T 68/85 (OJ EPO 1987, 228), cited by the appellant, the requirement of clarity demands not only that the skilled person be able to understand the wording of the claim but also that he be able to implement it (see T 68/85, point 8.4.3). In other words, the functional feature must be accompanied by instructions which are sufficiently clear for the expert to reduce them to practice. This implementation of the invention implies that means must be available to the skilled person, either from the patent application or from the common general knowledge at the relevant date of the application, to recognise and evaluate the technical effect of the functional definition.

When the claim is directed, according to the usual wording, to a further therapeutic application of a medicament and the condition to be treated is defined in functional terms, such as those in the claim under consideration, the skilled person must be given instructions, in the form of experimental tests or any testable criteria, allowing him to recognise which conditions fall within the functional definition and accordingly whether or not the therapeutic indication representing the heart of the invention falls within the scope of the claim.

3.1.2. In the present case, the invention is based on the discovery that the (R)-isomer of fluoxetine shows a high specificity for the serotonin 5-HTIC receptor. Accordingly, the claimed therapeutic indication of (R)-fluoxetine is the treatment of any condition susceptible of being improved or prevented by selective occupation of this specific receptor. The Board wishes to stress that the "selective occupation" of a receptor, although being indisputably a pharmacological effect, cannot in itself be considered a therapeutic application. The discovery on which the invention is based, even if representing an important piece of scientific knowledge, still needs to find a practical application in the form of a defined, real treatment of any pathological condition in order to make a technical contribution to the art and be considered an invention eligible for patent protection.

Specifically for this purpose, the description cites a list of examples of such conditions, namely obesity, bulimia, alcoholism, pain, sleep apnea, obsessive-compulsive disorders, substance abuse and migraine, intended to be treated according to the present invention.

Yet, due to the functional definition of the claimed subject-matter, the scope of claim 1 is not limited to the treatment of said specified conditions but, by contrast, embraces an undefined number of other conditions all allegedly capable of being improved or prevented by the selective occupation of the 5HTIC receptor. Under these circumstances, the independent claim can only be regarded as clear if means are available to the skilled person for assessing whether or not an additional condition, not expressly cited in the application, but nevertheless affected by the administration of (R)-fluoxetine is comprised in the scope of claim 1.

3.1.3. The appellant contends that this condition is indeed met by the invention since the skilled person is aware of the many animal models known for the different CNS disorders and useful for assessing a posteriori the improvement or prevention caused by (R)-fluoxetine. Therefore, in the applicant's opinion, the skilled person is indeed able to establish whether or not such a condition falls within the scope of the claim.

To corroborate these arguments, the appellant relied on the three experimental tests showing the effect on animal models of (R)-fluoxetine on migraine, OCD and pain (Annex Z of 14 February 2000).

3.1.4. The Board cannot concur with the appellant's opinion.

The selective occupation of the 5-HTIC receptor is only one of the pharmacological activities of fluoxetine, either as (R)-isomer or racemate. In fact, as described in document (5), pages 258 and 259 and table 4, fluoxetine additionally shows a serotonin-uptake inhibiting activity in the synapses and this activity would appear to amount to its main pharmacological effect. The teaching of document (5) is even confirmed by D. W. Robertson and D. T. Wong, the inventors mentioned in the present application, who suggested in the late-published document (4) that the inhibition of 5-HT uptake accounts for most of the enhancement of 5-HT transmission and other pharmacological responses in animals treated with fluoxetine or its congeners (see page 43, abstract, and page 46, "Discussion").

Accordingly, the experimental tests produced by the appellant in Annex Z have to be considered in the light of this, at least, double activity of fluoxetine. The tests demonstrate the therapeutic efficacy of (R)-fluoxetine in the treatment of migraine, OCD and pain, but, as is evident from the reading of their description, they fail to elucidate any mechanism leading to such an effect since they are devised simply to monitor a final, mainly behavioural, result. Therefore, these tests, while proving indeed a therapeutic activity of (R)-fluoxetine, do not solve the question of whether such therapeutic effects are caused by the occupation of the 5-HTIC receptor or by the concomitant 5-HT uptake inhibition or even by any other, so far unknown, effect of fluoxetine.

The view that neither the cited tests nor any other known test normally used to study CNS disorders are effective in elucidating the mechanism of action of (R)-fluoxetine was also confirmed at the oral proceedings by the appellant himself, who admitted that it had not been conclusively demonstrated that the reported therapeutic activity resulted from the selective occupation of the 5-HTIC receptor rather than from the 5-HT uptake inhibition.

Under these circumstances, the Board is of the opinion that at the filing date of the application no means involving testable criteria existed to assist the skilled person in assessing whether or not a "condition" improved or prevented by (R)-fluoxetine was comprised in the functional definition of the claimed subject-matter.

For these reasons, the Board holds that claim 1 does not meet the requirements of Article 84 EPC.

4. First auxiliary request

The expression "a condition which can be improved or prevented by selective occupation of the 5HTIC receptor" has been dropped from the text of claim 1 of the first auxiliary request, which is limited to the preparation of a medicament for the treatment of defined conditions, namely obesity, bulimia, alcoholism, pain, sleep apnea, obsessive-compulsive disorders, substance abuse or migraine. The claim as presently worded is regarded as clear.

4.1. Article 54 EPC

4.1.1. The amendments introduced in the definition of the claimed subject-matter have drastically changed the essence of the invention. For this reason, the Board considers that novelty of the claimed subject-matter, although not a point at issue in the decision under appeal, is now to be evaluated in the light of the cited prior documents, specifically document (1).

This document discloses the absolute configuration and the pharmacological activities of the (R)- and (S)- isomers of fluoxetine. Three in vivo studies are reported to show the effects of the separate isomers in (a) endogenous pain control and opiate-induced antinociception, (b) inhibition of the induced mouse brain serotonin depletion and (c) depression of palatability-induced ingestion (drinking). In all animal models the two isomers proved to be active with little enantiospecific differences. More specifically, in the endogenous pain control test, both (R) and (S) fluoxetine, when injected alone or in combination with a sub-analgesic dose of morphine, antagonised acetic acid-induced abdominal constriction, blocking writhing in a dose-dependent fashion, the (R) isomer being slightly more effective than the (S) isomer (see the heading "Pharmacology" on pages 1414 and 1415). The Board considers that the disclosure in document (1) of the ability of (R)-fluoxetine to control endogenous pain is prejudicial to the novelty of claim 1, which also envisages the treatment of a mammal suffering from or susceptible to pain.

4.1.2. During the oral proceedings, the appellant argued that document (1) does not actually disclose the preparation of a medicament within the meaning given in the present application or in claim 1. In fact, the experimentation was carried out on animals and without the intention of achieving a therapeutic effect, typically characterising a real therapeutic treatment.

The Board wishes, first of all, to stress that the (R)-fluoxetine solution injected into animals in the different test described in (1) is indeed to be considered as a "medicament", since it comprises a therapeutically active agent and it is suitable for use as a medicament, at least in animals.

Furthermore, the subject-matter of claim 1 is not a product but the use of a substance, known in itself, for the preparation of a medicament, also known in itself, for a specific therapeutic application, and that the novelty of this claim, if any, can only derive from the novelty of said therapeutic use.

It is a well-established and accepted principle that, for the purpose of patent protection of a medical application of a substance, a pharmacological effect or any other effect such as a behavioural effect observed either in vitro or on animal models is accepted as sufficient evidence of a therapeutic application if for the skilled person this observed effect directly and unambiguously reflects such a therapeutic application. This principle was laid down in decision T 158/96 dated 28 October 1998 ((1999) E.P.O.R., page 285) relating to an alleged therapeutic application, which, unlike the present one, was not made plausible by any such preliminary effect. On the contrary, the efficacy of (R)-fluoxetine in controlling acetic acid-induced abdominal constriction (writhing) and potentiating morphine-induced antinociception in mice, as shown in document (1), directly and unambiguously reflects one of the therapeutic applications cited in claim 1, namely the treatment of pain.

For this reason, the Board holds that the subject-matter of claim 1 is not novel in relation to the teaching in document (1).

5. Second auxiliary request

The above reasons cannot be maintained for the second auxiliary request.

Claim 1 according to this request is limited to three specified conditions, which are sleep apnea, substance abuse or migraine.

Even more so than in the case of the first auxiliary request, the amendments introduced in the text of claim 1. do not represent a simple limitation of the scope of the claim, but rather a radical change to the heart of the invention. Whereas the invention as filed or amended during the examination proceedings related to any condition susceptible of being improved or prevented by the selective occupation of the 5-HTIC receptor, after amendment it relates to three specific diseases, which were never cited as a characterising feature of a claim submitted to the examining division.

Under these circumstances, the Board avails itself of the discretionary power conferred by Article 111(1) EPC and remits the case to the examining division for further prosecution.

Order

ORDER

For these reasons it is decided that:

1. The decision under appeal is set aside,

2. The case is remitted to the department of first instance for further prosecution on the basis of the second auxiliary request as submitted during the oral proceedings.

Footer - Service & support
  • Service & support
    • FAQ
    • Contact us
    • Subscription centre
    • Official holidays
    • Publications
    • Procedural communications
    • Ordering
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
SoMe facebook 0
European Patent Office
EPO Jobs
SoMe instagram
EuropeanPatentOffice
SoMe linkedIn
European Patent Office
EPO Jobs
EPO Procurement
SoMe twitter
EPOorg
EPOjobs
SoMe youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility